Crataegus - Dr Willmar Schwabe Pharmaceuticals

Alternative Names: Crataegutt; WS 1442

Latest Information Update: 24 Dec 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dr. Willmar Schwabe Pharmaceuticals
Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
Mechanism of Action Free radical scavengers; Leucocyte elastase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Jul 2002 A study has been added to the adverse events and Heart Failure therapeutic trials sections
03 Mar 2000 A study has been added to the adverse events and the Heart Failure therapeutic trials sections
02 Jun 1998 Launched for Heart failure in Europe (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com